According to the degree of risk involved, MDR divided medical devices into four classes: Class A (low risk), Class B (low moderate risk), Class C (moderate high risk), and Class D (high risk). Cardiovascular devices that come under the D Category include bioresorbable vascular scaffold systems, drug-eluting stents, and heart valves. Stents are intricate, tiny, hollow structures with a cylindrical shape that are arranged into a ring pattern using struts and connecting components. The major drawback is postprocedural complications associated with stent implantation such as inflammation, thrombogenesis, and hyper-proliferation of vascular smooth muscle cells. Thus, estimating the prevalence of adverse events following stent implantation is the primary objective of the current research. A meta analysis of the literature on adverse events resulting from stent implantation was conducted for this study. A computerized search of the primary database literature was conducted from 2000 onwards. In total 102 case studies were selected as per inclusion/exclusion criteria. All studies were thoroughly examined about the type of stent, patient gender, age, reaction start time, adverse event, clinical presentation, treatments, and outcomes. Meta-analysis studies confirmed an incremental rise in adverse events with a significant increase in mortality and the risk of death was almost doubled with the presence of any co-morbidity. A lower target-lesion revascularization and incidence of stent thrombosis with newer-generation devices as compared to 1st generation DES and BMS. With the development and improvement of coronary stents, particularly second-generation DESs, the long-term outcome after PCI has improved dramatically. However, the combination of personalized medicine and an improved stent platform with cell-selective drugs has the potential to solve the remaining challenges and improve the care of coronary artery disease patients.